Health Canada has approved ixazomib (Ninlaro) for use in combination with lenalidomide and dexamethasone for the treatment of adults with relapsed/refractory multiple myeloma.
The U.S. Food and Drug Administration approved ixazomib in November 2015 for patients with relapsed/refractory multiple myeloma, based on data from TOURMALINE-MM1 that showed extended progression-free survival with a manageable safety profile.
VladimirSorokin/Thinkstock
“The approval of Ninlaro offers a much-needed new option for Canadian patients with multiple myeloma who have received at least one prior therapy. Its oral delivery may help multiple myeloma patients overcome some of the logistical burdens they may face with current therapies, which are typically administered in-clinic or in-hospital requiring significant travel and time constraints,” said Donna Reece, M.D., professor and director of the program for multiple myeloma and related diseases in the department of medical oncology and haematology at Princess Margaret Hospital/University of Toronto.
Ninlaro is marketed by Takeda. Click here to read the press release.